9 Major Cities Ease Restrictions, Foreign-Owned Single-Entity Hospitals Surge, Is There a Hidden Crisis Behind China's Economic Stimulus?
The Chinese government has announced that it will allow wholly foreign-owned hospitals to be set up in nine regions, including Beijing, in a bid to attract foreign investment and stimulate the economy to boost the flagging economy.
The Ministry of Commerce, the National Health Commission and the State Food and Drug Administration jointly issued a document, deciding to expand the pilot work in the field of biotechnology and wholly owned hospitals. In the field of biotechnology, foreign-invested enterprises will be allowed to engage in human stem cell, gene diagnosis and treatment technology development and technology application in the China (Beijing) Pilot Free Trade Zone, China (Shanghai) Pilot Free Trade Zone, China (Guangdong) Pilot Free Trade Zone and Hainan Free Trade Port. All products registered and approved for production will be available for use throughout the country. In the field of hospitals, we plan to set up wholly foreign-owned hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and the whole island of Hainan (except for traditional Chinese medicine, excluding the acquisition of public hospitals). Specific conditions, requirements and procedures will be notified separately.
In recent years, top foreign medical institutions have shown strong interest in the growth of China's high-end medical demand market. For example, Mayo Clinic of the United States has set up its first office in Shanghai United Family Hospital and plans to conduct long-term cooperation with China in joint treatment, international academic exchanges, clinical training and other areas to improve the accessibility of international cutting-edge medical technologies in China.
Experts pointed out that China's medical level has made remarkable progress in the past decades, especially in the field of treatment of certain diseases, and China's medical level has become a global leader. Chinese doctors have also accumulated rich experience in treatment. As early as 2014, the National Health and Family Planning Commission and the Ministry of Commerce allowed foreign investors to set up wholly foreign-owned hospitals in Beijing, Tianjin, Shanghai, Jiangsu, Fujian, Guangdong and Hainan through new facilities or mergers and acquisitions. The approval authority for the establishment of wholly foreign-owned hospitals is delegated to the provincial level, and its establishment and change shall be handled in accordance with relevant laws and regulations.
The new policy aims to attract foreign investment, promote high-quality development in China's medical related fields, and better meet the medical and health needs of the people. The new policy does not include mergers and acquisitions of TCM hospitals and public hospitals, and specific conditions, requirements and procedures will be announced soon. In addition, the policy allows companies with foreign investors to engage in the development and application of gene and human stem cell technologies for treatment and diagnosis in pilot free trade zones in Beijing, Shanghai, Guangdong and Hainan. The opening of these sectors comes against a backdrop of growth headwinds in the world's second-largest economy and low confidence among foreign businesses.
Looking for chemical products? Let suppliers reach out to you!
2026-07-16
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
McKinsey Pays to Close a Purdue Liability Chapter
Recommend Reading
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bearish Factors Exhausted, Hydrogen Peroxide Prices Still Have Room to Rise in Late May
-
Styrene-butadiene rubber market prices surge and then fall
-
This Week's PVC Prices Narrowly Declined in China
-
Cost-side support weakens, polyester staple fiber prices slightly decline
-
Manufacturers Continue to Push for Price Increases, Acrylonitrile Market Rises Slightly